Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mesoblast Ltd ADR (MESO)

Mesoblast Ltd ADR (MESO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,346,552
  • Shares Outstanding, K 128,297
  • Annual Sales, $ 17,200 K
  • Annual Income, $ -102,140 K
  • EBIT $ -62 M
  • EBITDA $ -56 M
  • 60-Month Beta 2.03
  • Price/Sales 132.12
  • Price/Cash Flow N/A
  • Price/Book 3.87

Options Overview Details

View History
  • Implied Volatility 90.80% (-8.92%)
  • Historical Volatility 49.65%
  • IV Percentile 28%
  • IV Rank 17.03%
  • IV High 250.17% on 12/18/24
  • IV Low 58.10% on 01/22/25
  • Expected Move (DTE 2) 0.85 (4.65%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,513
  • Volume Avg (30-Day) 1,793
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 38,477
  • Open Int (30-Day) 35,656
  • Expected Range 17.44 to 19.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.32 +27.72%
on 11/20/25
19.28 -5.13%
on 12/10/25
+3.52 (+23.83%)
since 11/14/25
3-Month
14.10 +29.72%
on 11/07/25
20.17 -9.34%
on 10/09/25
+2.69 (+17.24%)
since 09/16/25
52-Week
9.61 +90.32%
on 04/07/25
22.00 -16.86%
on 12/30/24
+6.19 (+51.16%)
since 12/16/24

Most Recent Stories

More News
Maxim Group Reaffirms Their Buy Rating on Mesoblast (MESO)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast yesterday. The company’s shares opened today at $19.33.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...

MESO : 18.29 (+3.27%)
MEOBF : 1.3500 (unch)
Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)

In a report released today, John Hester from Bell Potter maintained a Buy rating on Mesoblast Limited, with a price target of A$4.00. The company’s shares closed today at $1.90.Elevate Your Investing...

MESO : 18.29 (+3.27%)
MEOBF : 1.3500 (unch)
Canaccord Genuity Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)

In a report released on October 3, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Mesoblast Limited, with a price target of A$3.04. The company’s shares closed last Friday at $1.75.Elevate...

MESO : 18.29 (+3.27%)
MEOBF : 1.3500 (unch)
Which S&P 500 Move Matters?

MSFT : 476.39 (+0.33%)
MESO : 18.29 (+3.27%)
NFLX : 94.57 (+0.85%)
NVDA : 177.72 (+0.81%)
AAPL : 274.61 (+0.18%)
SMR : 17.12 (-1.67%)
OKLO : 83.51 (+1.43%)
MSB.AX : 2.800 (+1.08%)
BWXT : 173.20 (-0.67%)
AMZN : 222.56 (+0.01%)
DIS : 111.62 (+1.02%)
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD)...

MESO : 18.29 (+3.27%)
CTMX : 4.25 (+2.91%)
CSTL : 39.05 (+0.44%)
SPRO : 2.27 (-0.87%)
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance...

MESO : 18.29 (+3.27%)
KOD : 24.13 (+4.82%)
MNPR : 71.47 (-4.86%)
ARQT : 28.53 (-1.45%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 18.29 (+3.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 18.29 (+3.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). Such investors...

MESO : 18.29 (+3.27%)
Why Shares of Mesoblast Are Down Monday

The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.

MESO : 18.29 (+3.27%)
MSB.AX : 2.800 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

3rd Resistance Point 18.95
2nd Resistance Point 18.68
1st Resistance Point 18.49
Last Price 18.29
1st Support Level 18.03
2nd Support Level 17.76
3rd Support Level 17.57

See More

52-Week High 22.00
Last Price 18.29
Fibonacci 61.8% 17.27
Fibonacci 50% 15.81
Fibonacci 38.2% 14.34
52-Week Low 9.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar